Free tool
FAERS Monitor: Faslodex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021344 or its brand name (Faslodex, Fulvestrant). Reports on generic versions are filed under their own applications.
Reports
33,513
Serious
27,136
81% of reports
Hospitalization
7,682
Death reported
5,028
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malignant neoplasm progression4,341
- fatigue4,249
- nausea3,085
- death2,782
- diarrhoea2,684
- neutropenia2,542
- white blood cell count decreased2,247
- metastases to bone2,179
- neoplasm progression2,130
- asthenia1,812
- pain1,786
- metastases to liver1,779
- breast cancer metastatic1,696
- dyspnoea1,654
- vomiting1,605
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 63 |
| 2005 | 115 |
| 2006 | 128 |
| 2007 | 149 |
| 2008 | 166 |
| 2009 | 158 |
| 2010 | 141 |
| 2011 | 268 |
| 2012 | 541 |
| 2013 | 343 |
| 2014 | 346 |
| 2015 | 713 |
| 2016 | 1,522 |
| 2017 | 2,213 |
| 2018 | 2,278 |
| 2019 | 2,870 |
| 2020 | 3,607 |
| 2021 | 3,353 |
| 2022 | 3,238 |
| 2023 | 3,862 |
| 2024 | 2,760 |
| 2025 | 2,874 |
| 2026 | 1,805 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,020,646 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breast cancer metastaticSignal | 1,696 | 117.6 | 111.8 | 165,068 |
| metastases to boneSignal | 2,179 | 95.9 | 91.8 | 177,559 |
| metastases to liverSignal | 1,779 | 70.6 | 67.3 | 109,747 |
| neoplasm progressionSignal | 2,130 | 40.9 | 39.2 | 77,919 |
| malignant neoplasm progressionSignal | 4,341 | 27.7 | 27.0 | 107,635 |
| white blood cell count decreasedSignal | 2,247 | 13.3 | 12.7 | 25,069 |
| neutropeniaSignal | 2,542 | 11.9 | 11.5 | 25,151 |
| fatigueSignal | 4,249 | 3.4 | 3.3 | 7,586 |
| astheniaSignal | 1,812 | 3.0 | 2.9 | 2,502 |
| diarrhoeaSignal | 2,684 | 2.6 | 2.5 | 2,752 |
| nauseaSignal | 3,085 | 2.5 | 2.4 | 2,744 |
| vomitingSignal | 1,605 | 2.1 | 2.0 | 1,001 |
| deathSignal | 2,782 | 2.0 | 2.0 | 1,510 |
| dyspnoea | 1,654 | 1.8 | 1.8 | 644 |
| pain | 1,786 | 1.8 | 1.7 | 686 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.